Platelet Inhibitors and Monitoring Platelet Function: Implications for Bleeding

Hematology/Oncology Clinics of North America

Volumn 21, Issue 1, 2007, Pages 51-63

  Shore Lesserson, Linda ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; APROTININ; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PROTAMINE; THIENOPYRIDINE; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; WARFARIN;

APLASTIC ANEMIA; BLEEDING; BLOOD CLOTTING PARAMETERS; CARDIOPULMONARY BYPASS; DRUG POTENTIATION; HUMAN; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; BLOOD PLATELETS; DRUG MONITORING; HEMORRHAGE; HEMOSTASIS; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBELASTOGRAPHY;

EID: 33846366335     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.11.012     Document Type: Review

References (45)

1. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 17 (2003) S1-S5
2. Michelson A.D., MacGregor H., Barnard M.R., et al. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost 71 (1994) 633-640
3. Valeri C.R., Bougas J.A., Talarico L., et al. Behavior of previously frozen erythrocytes used during open-heart surgery. Transfusion 10 (1970) 238-246
4. Boldt J., Zickmann B., Czeke A., et al. Blood conservation techniques and platelet function in cardiac surgery. Anesthesiology 75 (1991) 426-432
5. Faraday N., and Rosenfeld B.A. In vitro hypothermia enhances platelet GPIIb-IIIa activation and P-selectin expression. Anesthesiology 88 (1998) 1579-1585
6. Upchurch G.R., Valeri C.R., Khuri S.F., et al. Effect of heparin on fibrinolytic activity and platelet function in vivo. Am J Physiol 271 (1996) H528-H534
7. John L.C., Rees G.M., and Kovacs I.B. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 105 (1993) 816-822
8. Ammar T., and Fisher C.F. The effects of heparinase 1 and protamine on platelet reactivity. Anesthesiology 86 (1997) 1382-1386
9. Carr Jr. M.E., and Carr S.L. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects. Thromb Res 75 (1994) 617-630
10. Rinder C.S., Mathew J.P., Rinder H.M., et al. Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology 75 (1991) 563-570
11. Ferraris V.A., Ferraris S.P., Singh A., et al. The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg 65 (1998) 352-358
12. Landis R.C., Asimakopoulos G., Poullis M., et al. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg 72 (2001) 2169-2175
13. Poullis M., Manning R., Laffan M., et al. The antithrombotic effect of aprotinin: actions mediated via the protease-activated receptor 1. J Thorac Cardiovasc Surg 120 (2000) 370-378
14. Coller B.S., Folts J.D., Scudder L.E., et al. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 68 (1986) 783-786
15. Tcheng J.E., and Campbell M.E. Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?. J Am Coll Cardiol 42 (2003) 1196-1198
16. Chan A.W., Moliterno D.J., Berger P.B., et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 42 (2003) 1188-1195
17. Bhatt D.L., Marso S.P., Lincoff A.M., et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 35 (2000) 922-928
18. Savi P., and Herbert J.M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31 (2005) 174-183
19. Bertrand M.E., Rupprecht H.J., Urban P., et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 102 (2000) 624-629
20. Savi P., Combalbert J., Gaich C., et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 72 (1994) 313-317
21. Hirsh J., and Bhatt D.L. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 164 (2004) 2106-2110
22. Savi P., Pereillo J.M., Uzabiaga M.F., et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84 (2000) 891-896
23. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
24. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
25. Smith S.C., Feldman T.E., Hirshfeld J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 113 (2006) 156-175
26. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
27. Herbert J.M., Dol F., Bernat A., et al. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 80 (1998) 512-518
28. Hongo R.H., Ley J., Dick S.E., et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 40 (2002) 231-237
29. Purkayastha S., Athanasiou T., Malinovski V., et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart 92 (2006) 531-532
30. Chen L., Bracey A.W., Radovancevic R., et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 128 (2004) 425-431
31. Rodgers R.P., and Levin J. Bleeding time revisited. Blood 79 (1992) 2495-2497
32. Rodgers R.P. Bleeding time tables. A tabular summary of pertinent literature. Semin Thromb Hemost 16 (1990) 21-138
33. Rodgers R.P. Supplementary bleeding time bibliography. Semin Thromb Hemost 16 (1990) 139-144
34. Elwood P.C., Beswick A.D., Sharp D.S., et al. Whole blood impedance platelet aggregometry and ischemic heart disease. The Caerphilly Collaborative Heart Disease Study. Arteriosclerosis 10 (1990) 1032-1036
35. Chandler W.L. The thromboelastography and the thromboelastograph technique. Semin Thromb Hemost 21 Suppl 4 (1995) 1-6
36. Davis C.L., and Chandler W.L. Thromboelastography for the prediction of bleeding after transplant renal biopsy. J Am Soc Nephrol 6 (1995) 1250-1255
37. Khurana S., Mattson J.C., Westley S., et al. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med 130 (1997) 401-411
38. Mobley J.E., Bresee S.J., Wortham D.C., et al. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 93 (2004) 456-458
39. Shore-Lesserson L., Fischer G., Sanders J., et al. Clopidogrel induces a platelet aggregation defect that is partially mitigated by ex-vivo addition of aprotinin. [abstract]. Anesthesiology 101 (2004) A-268
40. Smith S.M., Judge H.M., Peters G., et al. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets 15 (2004) 465-474
41. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103 (2001) 2572-2578
42. Bock M., De Haan J., Beck K.H., et al. Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol 106 (1999) 898-904
43. Escolar G., Cases A., Vinas M., et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica 84 (1999) 614-619
44. Campbell C.L., Berger P.B., Nuttall G.A., et al. Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study. Am Heart J 150 (2005) 796-799
45. Carville D.G., Schleckser P.A., Guyer K.E., et al. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol 30 (1998) 171-177